SUBSCRIBE
SUBSCRIBE
News   Policy

GlaxoSmithKline (JOBS) Says US Still Reviewing Clot Disorder Drug

September 22, 2008 | 
1 min read

WASHINGTON, Sept 19 (Reuters) - U.S. health officials still are reviewing GlaxoSmithKline Plc’s proposed clotting disorder drug Promacta, the company said on Friday.

Regulatory
MORE ON THIS TOPIC
Roche's signage at its office in France
Approvals
Roche Wins First-Line Breast Cancer Nod for Oral PI3K Blocker, Projects $2.3B in Peak Sales
October 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Teva Pharmaceuticals USA headquarters in
Legal
Teva to Pay $450M in Settlement With DOJ Over Kickback and Price-Fixing Allegations
October 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Drug Development
How AI Could Ease Tension in Clinical Trials
October 10, 2024
 · 
1 min read
 · 
Lori Ellis
Pictured: A scientist works behind an FDA sign/Tay
FDA Tracker
Third-Party Issues Delay Zealand’s Congenital Hyperinsulinism Drug
October 10, 2024
 · 
188 min read
 · 
Heather McKenzie